Difference between revisions of "Anti-Fibrinolytic"

From Practice Parameters
Jump to navigation Jump to search
(Created page with "==Section 8 - MEDICATION GUIDELINES== ===8.19 ANTI-FIBRINOLYTICS=== ====Tranexamic Acid (TXA)==== '''DESCRIPTION''' * Inhibits both plasminogen activation and plasmin activi...")
 
Line 7: Line 7:
 
* Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.
 
* Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.
 
'''INDICATIONS'''
 
'''INDICATIONS'''
* [[Shock|Severe Hemorrhagic Shock]].
+
* [[Severe Hemorrhagic Shock]].
 
'''CONTRAINDICATIONS'''
 
'''CONTRAINDICATIONS'''
 
* Isolated head injury
 
* Isolated head injury

Revision as of 07:57, 17 October 2018

Section 8 - MEDICATION GUIDELINES

8.19 ANTI-FIBRINOLYTICS

Tranexamic Acid (TXA)

DESCRIPTION

  • Inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation. With massive bleeding this may help stabilize clot formation and decrease extravascular bleeding.

INDICATIONS

CONTRAINDICATIONS

  • Isolated head injury
  • Known hypersensitivity
  • Age less than 16 years old
  • Known pregnancy

PRECAUTIONS

  • Rapid injection can cause hypotension

DOSAGE

  • 1000 mg of TXA mixed in 100 ml or 250 ml of normal saline infused via IO or IV over 10 minutes. Should be administered via a rate limiting device such as a Dial-A-Flo. A Buretrol is not a rate limiting device.